How Much Does Aduhelm Cost?
By
Simon Spichak, MSc
| September 12th, 2022
How much does Aduhelm cost? Even if you can cover the expense, that doesn’t mean the drug is easy to get. Aduhelm costs an…
More Aduhelm Drama: Packaging Could Waste Medicare Millions; Trial Tossed
By
Simon Spichak, MSc
| June 27th, 2022
New findings reveal that the way Aduhelm is packaged leads to wasted medication — and as much as $605 million per year of Medicare…
CMS Says No Aduhelm Coverage for Patients Outside Clinical Trials
By
Simon Spichak, MSc
| April 8th, 2022
The Centers for Medicare and Medicaid Services finalized its decision to limit the coverage of Alzheimer’s drug Aduhelm and future monoclonal antibodies. In February…
Does Aduhelm Work? Patients Weigh In on the Controversial Alzheimer’s Drug
By
Nicholas Chan
| November 1st, 2021
Following the approval of the Alzheimer’s drug Aduhelm — and the litany of controversy surrounding it — one question that’s top of mind for…
Some Hospitals Refuse to Offer Alzheimer’s Drug Aduhelm
By
Nicholas Chan
| July 15th, 2021
Two large hospitals, Cleveland Clinic and Mount Sinai, have decided against administering Aduhelm for patients following controversy around the Alzheimer’s drug’s FDA approval drug…
Medicare Is Deciding Now Whether To Cover Aduhelm—And All the Similar Drugs to Follow
By
Alexandra Marvar
| July 13th, 2021
Will Medicare cover Alzheimer’s drugs like Aduhelm? That decision-making process is underway. This week, the U.S. government embarked on the formal review process to…
FDA Head Calls for Investigation Into Controversial Aduhelm Approval
By
Simon Spichak
| July 12th, 2021
Image: Aduhelm, Biogen/AP. The head of the FDA, Dr. Janet Woodcock, calls for investigation into the agency’s own controversial approval of Biogen’s Aduhelm, the…
FDA Limits the Use of Aduhelm After Criticisms of Broad Approval
By
Nicholas Chan
| July 8th, 2021
Following sharp criticisms of the FDA’s broad approval of Aduhelm for all patients with Alzheimer’s, the agency has narrowed the drug’s label to those…
FDA Speeds Up Process for Two More Anti-Amyloids
By
Alexandra Marvar
| June 24th, 2021
The FDA will hasten the review of two more new Alzheimer’s drug candidates, Eli Lilly & Co.’s donanemab and Biogen and Eisai’s lecanemab. Today,…
The Questions Doctors Are Getting About Aduhelm Right Now—And Their Answers
By
Nicholas Chan
| June 24th, 2021
Image: Aduhelm, Biogen/AP. “The approach I’ve been taking is that each decision about whether or not to offer this as a treatment has to…
Will Insurance Companies and Medicare Cover Aduhelm’s High Price Tag?
By
Susanna Granieri
| June 21st, 2021
Biogen’s recently FDA-approved drug Aduhelm costs an upward of $56,000 per year, and this may have a domino effect of impacts: “If Aduhlem is…
A Retired Neurologist On His Experience With Aduhelm’s Side Effects
By
Nicholas Chan
| June 16th, 2021
Retired neurologist Daniel Gibbs speaks about his own Alzheimer’s diagnosis, his unusual and severe case of side effects in aducanumab (Aduhelm) clinical trials, and…
Amyloid Hypothesis in the Hot Seat After Aduhelm Approved for Alzheimer’s
By
Nicholas Chan
| June 11th, 2021
The FDA’s approval of Biogen’s new anti-amyloid drug Aduhelm was a landmark moment for Alzheimer’s — and it comes with no small amount of…
What Is Aduhelm and How Does It Fight Alzheimer’s?
By
Alexandra Marvar
| June 10th, 2021
Looking for answers about Alzheimer’s treatment Aduhelm (generic name aducanumab)? Here’s a primer on what it is, what it does, and more, according to…
Phil’s Journal: Aduhelm Is Greenlit to Treat Alzheimer’s—It’s Still Complicated
By
Phil Gutis
| June 9th, 2021
As an aducanumab trial participant, Phil Gutis, a reporter with early-stage Alzheimer’s, was part of Aduhelm’s journey to FDA approval. Doctors can soon start…